Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent’s existing contract for the acquisition of CYFENDUS. Deliveries are expected to begin this calendar year and be complete by April 2025. This award follows a previously announced contract modification of $30.0 million to supply CYFENDUS this year. CYFENDUS vaccine was approved by the U.S. Food & Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age. Anthrax is a Tier 1 biological select agent due to its potential to be used for a bioterrorist incident and threat to public health and national security.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EBS:
- WHO determines mpox upsurge still constitutes public health emergency
- Emergent BioSolutions files to sell 3.61M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- Emergent BioSolutions rises 31.2%
- Qualcomm, Moderna report quarterly beats: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
